Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04456673 · ClinicalTrials.gov registry record · Phase 3
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
A Phase 3 study of Chronic Obstructive Pulmonary Disease, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 935
- Enrollment target
- 20
- Study locations
NCT04456673 is a Phase 3 study of Chronic Obstructive Pulmonary Disease that has completed, run by Sanofi. The registered enrollment target is 935 participants, below the 1,743-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT04456673, a Phase 3 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 935 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by * Annualized rate of acute moderate or severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on * Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo * Health related quality of life, assessed by the change from baseline to Week 52 in the St. George's Respiratory Questionnaire (SGRQ) * Pre-bronchodilator FEV1 over 52 weeks compared to placebo * Lung function assessments * Moderate and severe COPD exacerbations * To evaluate safety and tolerability * To evaluate dupilumab systemic exposure and incidence of antidrug antibodies (ADA)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab SAR231893
- DRUG Inhaled Corticosteroid
- DRUG Inhaled Long-Acting Beta Agonist
- DRUG Inhaled Long-Acting Muscarinic Antagonist
Study Locations (20)
Florida
- Helix Biomedics, LLC Site Number : 8400035 - Boynton Beach
- Pioneer Clinical Research Site Number : 8400043 - Boynton Beach
- Renaissance Research and Medical Group, Inc Site Number : 8400092 - Cape Coral
- St. Francis Sleep, Allergy and Lung Institute Site Number : 8400020 - Clearwater
- Beautiful Minds Clinical Research Center Site Number : 8400081 - Cutler Bay
- Omega Research Consultants, LLC Site Number : 8400021 - DeBary
- Sciences Connections, LLC Site Number : 8400133 - Doral
California
- Kern Research, Inc Site Number : 8400031 - Bakersfield
- NewportNativeMD, Inc Site Number : 8400032 - Newport Beach
- Prospective Research Innovations, Inc. Site Number : 8400063 - Rancho Cucamonga
- ACRC Studies Site Number : 8400094 - San Diego
- Institute of HealthCare Assessment, Inc. Site Number : 8400015 - San Diego
- Allianz Research Institute Site Number : 8400007 - Westminster
Alabama
- Cullman Research Center, LLC Site Number : 8400095 - Cullman
- Pulmonary & Sleep Associates of Jasper PC Site Number : 8400090 - Jasper
- Scottsboro Quick Care Clinic Site Number : 8400116 - Scottsboro
Arizona
- Phoenix Medical Group Site Number : 8400061 - Peoria
- Medical Advancement Center of Arizona Site Number : 8400107 - Tempe
Arkansas
- Asthma and Allergy Institute Site Number : 8400022 - Little Rock
Colorado
- Innovative Clinical Research Site Number : 8400018 - Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 935 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2024-05-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04456673
The ClinicalTrials.gov registry entry for NCT04456673 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 935 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,743-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (46% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT04456673 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04456673 about?
NCT04456673 is a clinical study titled "Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation". Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by * Annualized rate of acute moderate or severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effec...
What is the current status of trial NCT04456673?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 935 participants. The study started on 2020-07-06. Estimated completion is 2024-05-27.
What conditions does trial NCT04456673 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT04456673?
The interventions under investigation include: Placebo (DRUG), Dupilumab SAR231893 (DRUG), Inhaled Corticosteroid (DRUG), Inhaled Long-Acting Beta Agonist (DRUG), Inhaled Long-Acting Muscarinic Antagonist (DRUG).
Who is sponsoring clinical trial NCT04456673?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04456673 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.